Seagen, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Seagen, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: targeted drug combo enters phase 3
Disease control Recruiting nowThis study tests whether adding tucatinib and trastuzumab to standard chemotherapy helps people with HER2-positive colorectal cancer that has spread or can't be removed. About 400 participants will be randomly assigned to the new combo or standard treatment. The goal is to see if…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo shows promise for tough bladder cancer
Disease control Recruiting nowThis phase 2 trial is testing whether the drug disitamab vedotin, alone or with pembrolizumab, can shrink tumors in people with advanced bladder cancer that has spread or cannot be removed. The study includes 372 participants whose cancer cells have a protein called HER2. Researc…
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called SEA-CD70, alone or with standard drugs azacitidine and venetoclax, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goal is to check safety and find the right dose. About 178 participants will b…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New cancer drug sigvotatug vedotin enters human trials
Disease control Recruiting nowThis early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC